Clinical guideline
2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting
ESMO Open · 2024
Other areas and general studies
84 items with a structured summary
Clinical guideline
Management of Fatigue in Adult Survivors of Cancer: ASCO–Society for Integrative Oncology Guideline Update
JCO · 2024
113 randomised trialsEvidence base
Clinical guideline
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
Annals of Oncology · 2024
Advanced non-squamous non-small-cell lung cancer, prostate cancer, colorectal cancer, cholangiocarcinoma and ovarian cancerCancers for which NGS was already recommended in 2020
Clinical guideline
Vaccination of Adults With Cancer: ASCO Guideline
JCO · 2024
102 publicationsTotal number of publications included in the systematic review
Clinical guideline
2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents
Support Care Cancer · 2023
46 referencesNumber of new relevant references
Clinical guideline
2023 updated MASCC/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents
Support Care Cancer · 2023
342 papersPapers identified in the systematic review
Clinical guideline
Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update
JCO · 2023
17 systematic reviews ± meta-analyses + 44 randomised trialsEvidence base
Clinical guideline
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
European Heart Journal · 2022
Clinical guideline
American Cancer Society nutrition and physical activity guideline for cancer survivors
CA A Cancer J Clinicians · 2022
68%5-year relative survival for all cancers combined
Clinical guideline
Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline
JCO · 2022
52 systematic reviews (42 exercise, 9 diet, 1 weight management) plus 23 randomised controlled trialsVolume of evidence
Clinical guideline
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Annals of Oncology · 2022
Clinical guideline
Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines☆
ESMO Open · 2021
Clinical guideline
ESPEN practical guideline: Clinical Nutrition in cancer
Clinical Nutrition · 2021
43 recommendationsNumber of recommendations given
Clinical guideline
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
JCO · 2021
Clinical guideline
Antiemetics: ASCO Guideline Update
JCO · 2020
3 publications from the updated searchUpdated systematic review (1 June 2016 to 24 January 2020)
Clinical guideline
Cancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis and treatment
Annals of Oncology · 2020
Clinical guideline
Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines†
Annals of Oncology · 2020
Clinical guideline
Management of Cancer Cachexia: ASCO Guideline
JCO · 2020
20 systematic reviews and 13 additional randomised controlled trialsVolume of evidence included
Clinical guideline
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
Cancer · 2020
1197 papersNumber of papers used
Clinical guideline
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update
JCO · 2020
257 referencesNew references identified in the search
Clinical guideline
Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable
Medicine & Science in Sports & Exercise · 2019
Exercise training and exercise testing are generally safe for cancer survivorsSafety
Clinical guideline
Systematic review of basic oral care for the management of oral mucositis in cancer patients and clinical practice guidelines
Support Care Cancer · 2019
17 papers on six interventionsNumber of new papers reviewed
Clinical guideline
Systematic review of oral cryotherapy for the management of oral mucositis in cancer patients and clinical practice guidelines
Support Care Cancer · 2019
114 papers (44 from PubMed and 70 from Web of Science)Papers identified
Clinical guideline
Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines
Support Care Cancer · 2019
Recommendation for haematopoietic stem cell transplantation, head and neck radiotherapy (without chemotherapy) and head and neck radiotherapy with chemotherapyPrevention of OM and the associated pain with PBM
Clinical guideline
Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update
JCO · 2018
6 new or updated meta-analyses and 6 new primary studiesEvidence added to the systematic review
Clinical guideline
Interventions to Address Sexual Problems in People With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario Guideline
JCO · 2018
Clinical guideline
Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update
JCO · 2018
6 new or updated meta-analyses and 6 new primary studiesEvidence added to the systematic review
Clinical guideline
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update
Clin Pharma and Therapeutics · 2017
Clinical guideline
ESPEN guidelines on nutrition in cancer patients
Clinical Nutrition · 2017
Clinical guideline
Management of febrile neutropaenia: ESMO Clinical Practice Guidelines
Annals of Oncology · 2016
Clinical guideline
Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up
Annals of Oncology · 2015
Clinical guideline
Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update
JCO · 2015
tbo-filgrastim and filgrastim-sndz added to the recommendationsAddition of new agents
Clinical guideline
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
Eur J Nucl Med Mol Imaging · 2014
Clinical guideline
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
European Journal of Cancer · 2011
Risk ≥20%Chemotherapy regimens with high FN risk
Clinical guideline
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
Clinical Infectious Diseases · 2011
Clinical guideline
Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update
JCO · 2018
61 publicationsNumber of publications identified and reviewed
Clinical guideline
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
JCO · 2017
41 publicationsNumber of publications included in the systematic review
Clinical guideline
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients
Annals of Oncology · 2016
Other
Cancer statistics, 2026
CA A Cancer J Clinicians · 2026
About 2,114,850 casesNew cancer cases (2026 projection, United States)
Review article
Personalized mRNA Neoantigen Vaccines in Cancer: Linking Precision Antigen Selection, Immune Remodeling, and Checkpoint Blockade
Int. J. Mol. Sci. · 2026
Other
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
Nature · 2024
Potent activity across various RAS genotypesActivity against RAS-addicted tumours
Other
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
CA A Cancer J Clinicians · 2024
Nearly 20 millionNew cancer cases in 2022 (including non-melanoma skin cancers)
Meta-analysis
Non-medical interventions to enhance return to work for people with cancer
Cochrane Database of Systematic Reviews · 2024
RR 1.09 (95% CI 0.96–1.24)Psycho-educational interventions: return to work
Review article
Antibody–drug conjugates come of age in oncology
Nat Rev Drug Discov · 2023
Meta-analysis
Dietary sugar consumption and health: umbrella review
BMJ · 2023
73 meta-analyses and 83 health outcomes from 8601 unique articlesVolume of evidence included
Review article
Hallmarks of Cancer: New Dimensions
Cancer Discovery · 2022
Phenotypic plasticity and disrupted cellular differentiationProposed independent hallmark
Clinical trial
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer
N Engl J Med · 2020
5.6% vs 7.9%Recurrent venous thromboembolism (primary outcome)
Other
Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis
The Lancet Global Health · 2020
2.2 million cases; ASIR 25.0 per 100,000 person-yearsTotal infection-attributable cancer cases in 2018
Clinical trial · Phase 2
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
JCO · 2020
28 months vs 50 monthsMedian overall survival
Clinical trial
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer
N Engl J Med · 2019
4.2% vs 10.2%Venous thromboembolism at 180 days (primary outcome)
Other
Cancer incidence in Iran in 2014: Results of the Iranian National Population-based Cancer Registry
Cancer Epidemiology · 2019
112,131 cases, of which 60,469 (53.9%) were in menTotal new cancer cases registered in 2014
Review article
Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors
Annals of Oncology · 2019
Memory, processing speed, attention and executive functionsCognitive domains most affected after chemotherapy
Review article
Hair disorders in patients with cancer
Journal of the American Academy of Dermatology · 2019
Clinical trial
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer
N Engl J Med · 2019
6.0% vs 8.8%Venous thromboembolism or related death up to day 180 (primary endpoint)
Clinical trial
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)
J Clin Oncol · 2018
4% vs 11%Venous thromboembolism recurrence at 6 months (cumulative rate; primary outcome)
Meta-analysis
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
JAMA Oncol · 2018
613 casesNumber of fatal ICI toxic events reported in Vigilyze (2009 to January 2018)
Review article
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
N Engl J Med · 2018
Meta-analysis
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens
JAMA Oncol · 2018
Odds ratio (OR) 3.81Hypothyroidism: combination therapy versus ipilimumab
Observational study
Pathogenic Germline Variants in 10,389 Adult Cancers
Cell · 2018
853 variants in 8% of 10,389 casesPathogenic or likely pathogenic variants
Review article
Chemotherapy‐induced peripheral neuropathy: A current review
Annals of Neurology · 2017
Approximately 30 to 40%Incidence of chemotherapy-induced peripheral neuropathy (CIPN) in patients treated with neurotoxic chemotherapy
Meta-analysis
Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue
JAMA Oncol · 2017
WES 0.30 (95% CI 0.25–0.36)Exercise interventions
Clinical trial · Phase 2
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Science · 2017
53% of patientsObjective radiographic response
Review article
The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging
CA A Cancer J Clinicians · 2017
Review article
Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting
N Engl J Med · 2016
Observational study
Familial Risk and Heritability of Cancer Among Twins in Nordic Countries
JAMA · 2016
27,156 cancers in 23,980 individuals; cumulative incidence 32%Incident cancers
Clinical trial · Phase 3
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting
N Engl J Med · 2016
74% vs 45% (olanzapine vs placebo)No nausea in the first 24 hours after chemotherapy
Review article
Cancer-related fatigue—mechanisms, risk factors, and treatments
Nat Rev Clin Oncol · 2014
Meta-analysis
Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis
Pain · 2014
68.1%CIPN prevalence in the first month after chemotherapy
Clinical trial
Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy
JAMA · 2013
1.06 (95% CI 0.72–1.40) vs 0.34 (95% CI 0.01–0.66)Reduction in average pain during the first 5 weeks of treatment (duloxetine vs placebo)
Clinical trial · Phase 3
Wisconsin Ginseng (Panax quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind Trial, N07C2
JNCI Journal of the National Cancer Institute · 2013
14.4 (SD 27.1) vs 8.2 (SD 24.8)Change from baseline in MFSI-SF general subscale at week 4
Clinical trial · Phase 3
One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor
JAMA · 2012
HR 0.46 (95% CI 0.32–0.65)Recurrence-free survival (RFS): hazard ratio
Review article
Tumor Markers in Clinical Practice: A Review Focusing on Common Solid Cancers
Med Princ Pract · 2012
Faecal occult blood testColorectal cancer screening
Review article
Employment and work-related issues in cancer survivors
Critical Reviews in Oncology/Hematology · 2011
63.5% of cancer survivors (range 24 to 94%)Return to work
Review article
Tumour seeding following percutaneous needle biopsy: The real story!
Clinical Radiology · 2011
Clinical trial · Phase 3
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
The Lancet · 2009
98% (95% CI 96–100) vs 83% (78–88)Recurrence-free survival at 1 year
Meta-analysis
Cancer Survivors and Unemployment
JAMA · 2009
33.8% vs 15.2%; pooled RR 1.37Unemployment in all cancer survivors vs controls
Meta-analysis
Impact of Primary Prophylaxis With Granulocyte Colony-Stimulating Factor on Febrile Neutropenia and Mortality in Adult Cancer Patients Receiving Chemotherapy: A Systematic Review
JCO · 2007
45% reduction (RR = 0.55; 95% CI 0.33–0.90)Infection-related mortality
Review article
Increased 18F-Fluorodeoxyglucose Uptake in Benign, Nonphysiologic Lesions Found on Whole-Body Positron Emission Tomography/Computed Tomography (PET/CT): Accumulated Data From Four Years of Experience With PET/CT
Seminars in Nuclear Medicine · 2007
More than 25% of studiesFrequency of benign non-physiological 18F-FDG uptake (6-month review of reports)
Clinical trial
Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial
Lancet · 2005
84% vs 57%Ability to walk after treatment
Review article
The role of radiotherapy in cancer treatment
Cancer · 2005
52%Proportion of cancer patients with an indication for external beam radiotherapy based on the best available evidence
Clinical trial
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
N Engl J Med · 2002
79 patients (53.7%)Partial response
Other
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
JCO · 1989
r = 0.85Correlation of carboplatin plasma clearance with GFR (18 patients)
Clinical trial · Phase 3
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
The Lancet · 2021
18.1 months (95% CI 16.8–21.4) vs 14.1 months (12.4–16.2)Median overall survival
Clinical trial
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
N Engl J Med · 2018
12.8% vs 13.5%Recurrent venous thromboembolism or major bleeding at 12 months (primary endpoint)
Nothing found.